skynesher/E+ via Getty Images Ipsen ( OTCPK:IPSEY ) and Foreseen Biotechnology on Thursday announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate, which targets a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation. Preclinical efficacy of FS001 was demonstrated in multi-drug resistant cancer models. The agreement gives Ipsen ( OTCPK:IPSEY ) exclusive worldwide rights to develop, manufacture and commercialize FS001, the companies said.
“We are excited to add FS001, the second ADC Ipsen has in-licensed this year, to our growing pipeline,” said Mary Jane Hinrichs, SVP and Head of Early Development at Ipsen ( OTCPK:IPSEY ). “As we prepare for the initiation of a Phase I clinical trial, we will evaluate FS001 in selected solid tumor types, which we hope will deliver critical new treatments for people living with cancer around the world.” Source: Press Release More on Ipsen S.
A. Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China Ipsen expands collaboration agreement with Exelixis Historical earnings data for Ipsen S.A.
Dividend scorecard for Ipsen S.A. Financial information for Ipsen S.
A..
